Payment overview · 2025
General Payments
$626.92
31 reported records · 14 companies
Healthcare provider profile · identity verified
John Edward Dolatowski, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOBART, IN · NPI 1205922218
Verified facts
What the public records show
CMS Open Payments records show John Edward Dolatowski, M.D. received $626.92 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 27.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $172.30 | 27.5% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $95.30 | 15.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $71.91 | 11.5% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $55.77 | 8.9% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $47.25 | 7.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.66 | 6.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.56 | 3.6% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $21.30 | 3.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.16 | 3.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.66 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.11 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.51 | 2.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.71 | 2.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.72 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $530.11 | 28 |
| Education | $96.81 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $80.28 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.54 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $55.77 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $51.22 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $47.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.66 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.66 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 111 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 193 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
84 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
111 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
193 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
64 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 582 | 179 |
| Losartan Potassium | Losartan Potassium | 427 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 407 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 293 | 85 |
| Escitalopram Oxalate | Escitalopram Oxalate | 224 | 62 |
| Montelukast Sodium | Montelukast Sodium | 221 | 76 |
| Glipizide | Glipizide | 197 | 55 |
| Ozempic | Semaglutide | 193 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 66 |
| Omeprazole | Omeprazole | 184 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 57 |
| Furosemide | Furosemide | 162 | 51 |
| Gabapentin | Gabapentin | 142 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 25 |
| Metformin Hcl | Metformin Hcl | 136 | 42 |
| Alprazolam | Alprazolam | 131 | 33 |
| Simvastatin | Simvastatin | 129 | 34 |
| Allopurinol | Allopurinol | 123 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 23 |
| Mounjaro | Tirzepatide | 111 | 31 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 105 | 40 |
| Lisinopril | Lisinopril | 102 | 27 |
| Prednisone | Prednisone | 99 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 26 |
| Azithromycin | Azithromycin | 67 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 31 |
| Solifenacin Succinate | Solifenacin Succinate | 67 | 24 |
| Finasteride | Finasteride | 66 | 14 |
| Rybelsus | Semaglutide | 64 | 26 |
| Eliquis | Apixaban | 63 | 13 |
| Carvedilol | Carvedilol | 59 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 16 |
| Trulicity | Dulaglutide | 50 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 45 | 16 |
| Sertraline Hcl | Sertraline Hcl | 45 | 11 |
| Spironolactone | Spironolactone | 45 | 14 |
| Meclizine Hcl | Meclizine Hcl | 44 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 11 |
| Trazodone Hcl | Trazodone Hcl | 42 | 16 |
| Meloxicam | Meloxicam | 41 | 11 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 11 |
| Baclofen | Baclofen | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Famotidine | Famotidine | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | 12 |
| Cefadroxil | Cefadroxil | 34 | 24 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | 17 |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | 12 |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Minoxidil | Minoxidil | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $626.92 · 31 records | Novo Nordisk Inc | AIRSUPRA, AUSTEDO XR, Cologuard Collection Kit, Dexcom G6 Transmitter, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, GVOKE HYPOPEN, INGREZZA, Kerendia, MOUNJARO, Ozempic, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error